Home / Business and Economy / EU Shuts Edwards Lifesciences Probe Over Policy Change
EU Shuts Edwards Lifesciences Probe Over Policy Change
16 Feb
Summary
- EU antitrust regulators closed an investigation into Edwards Lifesciences.
- The company withdrew its global unilateral anti-copycat policy.
- An Indian rival had filed a complaint against the policy.
European Union antitrust regulators have concluded their investigation into U.S. medical device manufacturer Edwards Lifesciences. The probe was initiated in September 2023 following concerns that the company might have been abusing its dominant market position.
An Indian competitor, Meril, had lodged a complaint with the European Commission regarding Edwards Lifesciences' global unilateral pro-innovation policy, often referred to as an anti-copycat policy. This policy had been a point of contention in patent disputes worldwide.
Edwards Lifesciences has since officially withdrawn its Global Unilateral Pro-Innovation (Anti-Copycatting) Policy (UPIP). The policy is no longer in effect and has been removed from the company's website. The European Commission stated that these actions have addressed the investigated concerns, and further action at the EU level is not prioritized.
Failure to comply with EU antitrust regulations can result in significant fines, potentially reaching up to 10% of a company's global annual turnover.
